Silence Therapeutics plc (NASDAQ:SLN) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $57.20.

SLN has been the topic of several recent research reports. Jefferies Financial Group assumed coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Morgan Stanley reaffirmed an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Monday, December 9th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th.

Hedge Funds Weigh In On Silence Therapeutics

Hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. acquired a new position in shares of Silence Therapeutics during the 3rd quarter worth approximately $56,000. Quarry LP purchased a new stake in Silence Therapeutics in the 2nd quarter worth $114,000. Verition Fund Management LLC acquired a new position in Silence Therapeutics during the third quarter worth $207,000. Custom Index Systems LLC purchased a new position in Silence Therapeutics during the second quarter valued at $282,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Silence Therapeutics during the third quarter valued at $318,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Down 2.8 %

Shares of NASDAQ SLN opened at $6.33 on Friday. Silence Therapeutics has a 52 week low of $5.81 and a 52 week high of $27.72. The business’s 50 day moving average price is $12.93 and its 200 day moving average price is $16.79. The firm has a market cap of $189.44 million, a P/E ratio of -4.03 and a beta of 1.05.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.